Tune Therapeutics, an epigenome-editing company based in Durham and Seattle, will be the first to initiate a human clinical trial for an epigenetic therapy for a common infectious disease.
About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.
The team recruited 46 adult women and men diagnosed with either MASLD, or MASH, or MASH with cirrhosis; compared them with eight patients who had non-MASH-related liver cirrhosis. These were also ...